Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery

AIM: Pharmacogenetic studies have identified the presence of the HLA-A*31:01 allele as a predictor of cutaneous adverse drugs reactions (ADRs) to carbamazepine. This study aimed to ascertain the preferences of patients and clinicians to inform carbamazepine pharmacogenetic testing services. METHODS:...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Clin Pharmacol
Päätekijät: Powell, Graham, Holmes, Emily A F, Plumpton, Catrin O, Ring, Adele, Baker, Gus A, Jacoby, Ann, Pirmohamed, Munir, Marson, Anthony G, Hughes, Dyfrig A
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Ltd 2015
Aiheet:
Pharmacogenetics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631187/
https://ncbi.nlm.nih.gov/pubmed/26138622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12715
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia